Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Authors
Keywords
Obesity, Drug withdrawal, Adverse drug reaction, Systematic review
Journal
BMC Medicine
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-22
DOI
10.1186/s12916-016-0735-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA-Approved Anti-Obesity Drugs in the United States
- (2016) Homayoun L. Daneschvar et al. AMERICAN JOURNAL OF MEDICINE
- Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
- (2016) Igho J. Onakpoya et al. BMC Medicine
- Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance
- (2016) L Aagaard et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis
- (2015) Igho J Onakpoya et al. BMC Medicine
- Management of obesity: improvement of health-care training and systems for prevention and care
- (2015) William H Dietz et al. LANCET
- Medical treatment of obesity: The past, the present and the future
- (2014) George A. Bray BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Tolerability and Safety of the New Anti-Obesity Medications
- (2014) Vojtech Hainer et al. DRUG SAFETY
- Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status
- (2014) John Cawley et al. PHARMACOECONOMICS
- Approval of antiobesity drug is "major regression for patients' safety," says health watchdog
- (2014) N. Hawkes BMJ-British Medical Journal
- The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate
- (2014) Steven Woloshin et al. JAMA Internal Medicine
- Antiobesity Pharmacotherapy: New Drugs and Emerging Targets
- (2013) G W Kim et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Drug Treatment of Obesity in Cardiovascular Disease
- (2012) Marietta Charakida et al. American Journal of Cardiovascular Drugs
- The Return of Rainbow Diet Pills
- (2012) Pieter A. Cohen et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Anti-obesity drugs: past, present and future
- (2012) R. J. Rodgers et al. Disease Models & Mechanisms
- Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
- (2012) Paul Hodgkins et al. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
- A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes
- (2012) Emmanuel J. M. Mignot Neurotherapeutics
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France
- (2012) Agnès Fournier et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Lorcaserin for Weight Loss: Insights Into US Food and Drug Administration Approval
- (2012) Larry E. Miller Journal of the Academy of Nutrition and Dietetics
- Anti-Obesity Drugs: A Review about Their Effects and Safety
- (2012) Jun Goo Kang et al. Diabetes & Metabolism Journal
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More